[6-(4-Cyclopropylpiperazin-1-yl)pyrimidin-4-yl]-[2-methyl-5-(1-methylcyclopropyl)oxyphenyl]methanimine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: [6-(4-Cyclopropylpiperazin-1-yl)pyrimidin-4-yl]-[2-methyl-5-(1-methylcyclopropyl)oxyphenyl]methanimine
• 英文别名: [6-(4-cyclopropylpiperazin-1-yl)pyrimidin-4-yl]-[2-methyl-5-(1-methylcyclopropyl)oxyphenyl]methanimine
• 化学式: C₂₃H₂₉N₅O
• 分子量: 391.5
• InChiKey: IDFRBCXRQKHOFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  65.3
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY<br/>[FR] COMPOSÉS INHIBANT L'ACTIVITÉ ENZYMATIQUE DE LA KINASE À MOTIFS RÉPÉTÉS RICHES EN LEUCINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014137723A1

  公开（公告）日：2014-09-12

  The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及吲唑类化合物，这些化合物是LRRK2激酶的有效抑制剂，并且在治疗或预防LRRK2激酶参与的疾病，如帕金森病中有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗LRRK-2激酶参与的这类疾病中使用这些化合物和组合物。